Read More

HUTCHMED Announced License To Takeda To Develop And Commercialize Fruquintinib Outside China; Hutchmed To Receive $400M Upfront On Deal Closing; Up To 730M In Potential Future Milestone Payments Plus Royalties On Net Sales

HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:​HCM, HKEX:​13) today announces that its subsidiary, HUTCHMED Limited, has entered into an exclusive license agreement with a subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502, NYSE:TAK) to further the global development, commercialization and manufacture of fruquintinib outside of mainland China, Hong Kong and Macau, where it is market

HCM

Read More

Pliant Therapeutics Earlier Announced Data From The Integris-IPF Phase 2a Trial Demonstrating Bexotegrast 320 Mg Was Well Tolerated And Achieved Statistically Significant FVC Increase In Patients With Idiopathic Pulmonary Fibrosis; Trial Met Primary An…

Pliant Therapeutics, Inc. (NASDAQ: PLRX) today announced 12-week interim data from the 320 mg dose group of INTEGRIS-IPF, a multinational, randomized, double-blind, placebo-controlled Phase 2a clinical trial of bexotegrast (PLN-74809) in patients with idiopathic pulmonary fibrosis (IPF).

PLRX

Read More

International Paper To Invest $103M in Cedar River Mill

nternational Paper (NYSE: IP) today announced formal plans to invest approximately $103 million to build and operate two natural gas power boilers to generate steam for its Containerboard Mill in Cedar Rapids, Iowa. Construction is set to begin in the second quarter of this year and be fully operational by the end of 2025.

IP